動物用ワクチン市場：製品タイプ、動物タイプ、疾患タイプ、投与経路、流通チャネル別-2025-2030年の世界予測

動物用ワクチン市場は、2024年には136億9,000万米ドルとなり、2025年には145億8,000万米ドル、CAGR 6.75%で成長し、2030年には202億7,000万米ドルに達すると予測されています。

近年、動物用ワクチン市場は、動物の健康、食糧安全保障、公共の安全に対する意識の高まりに後押しされ、世界の保健分野において重要なセグメントとして浮上しています。本レポートでは、この分野を再構築しつつある進化する動向、技術的進歩、戦略的要請を詳細に調査しています。科学、規制、市場の需要のダイナミックな相互作用により、製品のイノベーションと宿主生物学への鋭い理解が必要となる機会と課題が生み出されています。このイントロダクションでは、新規ワクチン開発の役割、確かな臨床データの重要性、市場導入に影響を与える規制の変化など、主要なテーマを概説し、舞台を整えます。ワクチンの送達方法と製剤化技術における現在進行中の改良は、獣医師と家畜管理者の予防的動物医療への取り組み方を再定義する変革期を意味します。この包括的な分析をさらに掘り下げることで、現在の慣行と将来の成長見通しの両方が明らかになり、意思決定者が新たな市場シグナルに戦略を合わせることができるようになります。

動物用ワクチンの世界の動向は、増え続ける研究開発活動、先端バイオテクノロジーの統合、戦略的提携によって特徴付けられています。こうした動向はイノベーションを促進するだけでなく、利用可能なワクチン製品の幅を広げています。利害関係者が規制の複雑さや競合のプレッシャーを乗り越えていく中で、こうした変化を理解することは、投資や経営の優先順位を長期的な市場の現実と一致させるために不可欠となります。

市場力学の変革期

動物用ワクチン市場は現在、業界力学を再構築し、競合情勢を再定義するような変革期を迎えています。新たなテクノロジーは機敏な製造プロセスへの道を開き、新規ワクチン候補の市場投入までの時間を大幅に短縮しています。遺伝子工学とバイオテクノロジーにおける極めて重要な進歩により、従来のワクチン製剤からmRNAワクチンや組み換えワクチンといった革新的なアプローチへの移行が顕著になっています。この変革は、科学的なブレークスルーだけに起因するものではなく、有効性、安全性、疾病発生への迅速な対応を重視する規制の枠組みの進化にも影響されています。

投資パターンにも顕著な変化が生じており、研究開発への資金拠出が増加することで、動物用予防接種に対するより個別化されたアプローチが可能になりつつあります。業界の利害関係者は現在、データ分析と最先端の診断ツールを活用して、さまざまな動物種に特有の疾病プロファイルを評価し、より的を絞ったワクチンソリューションにつなげています。さらに、デジタルヘルスプラットフォームの統合により、ワクチン接種後の転帰をモニターする能力が強化され、実世界での有効性が臨床試験の主張を確実に裏付けています。このようなデジタルの移行は、継続的なフィードバックと適応的な製造が標準となる環境を作り出し、より弾力的で応答性の高いサプライチェーンを支えています。

また、研究機関、バイオ製薬企業、獣医師間の共同事業も重視されるようになっています。このような提携は、科学を実行可能な市場ソリューションに変換するために、専門知識を結集して活用する上で極めて重要です。結局のところ、より技術的な力を持ち、データ情報に基づいた業界へのシフトは、動物の健康状態の改善、リスクの最小化、そして長期的にはより持続可能なワクチン市場の可能性を強調するものです。

動物用ワクチンの主要セグメントに関する洞察

動物用ワクチン市場を詳細に分析すると、この分野の多様性と奥深さを理解するための複数のセグメンテーション戦略が明らかになります。不活化ワクチン、弱毒生ワクチン、mRNAワクチン、遺伝子組換えワクチン、サブユニットワクチンを含む広範なスペクトルを包含する製品セグメンテーションは特に注目に値します。これらの分類は、様々な生物種における免疫反応を最適化するために設計された技術的進歩や複雑な製造プロセスを示しています。このように製品プロファイルが多様化することで、利害関係者は特殊なニーズに対応し、動物の健康に関する個別の課題に沿ったソリューションをオーダーメイドできるようになります。

さらに、動物の種類に基づくセグメンテーションによって、市場の洞察がさらに深まる。市場はコンパニオンアニマルと家畜を区別しており、前者は主にネコとイヌに代表され、後者はウシ、家禽、ヒツジ、ブタを含み、それぞれ異なる需要パターンと規制要件を牽引しています。このようなセグメンテーションは、ワクチン投与プロトコルのばらつきや、各セグメントを支える経済的配慮の違いを説明するものです。例えば、コンパニオンアニマル・ワクチンは、飼い主の嗜好や予防的健康対策によって推進されることが多いが、畜産動物用のワクチンは、厳格な食品安全基準やバイオセキュリティ規制に適合する必要があります。

病気の種類に基づくセグメンテーションでは、細菌感染、真菌感染、寄生虫感染、ウイルス感染に焦点を当てることで、さらに細かなレイヤーを追加しています。この枠組みの中で、細菌感染症はさらにクロストリジウム、大腸菌、レプトスピラ症、パスツレラ症に分けられ、寄生虫感染症は外部寄生虫と内部寄生虫に区別されます。ウイルス感染症は、鳥インフルエンザ、牛ウイルス性下痢症ウイルス、口蹄疫ウイルス、ニューカッスル病ウイルス、豚繁殖・呼吸器症候群ウイルス、狂犬病ウイルスなど、いくつかの重要な病原体をカバーしています。これらの詳細なサブカテゴリーは、特定の病原体とワクチン反応との相互作用が、臨床、物流、財務の各領域における技術革新と市場セグメンテーションをどのように促進しているかを示しています。

さらに、投与経路を分析することで、ワクチン設計の実際的な意味合いについての洞察が得られます。分類には注射用ワクチンと経口ワクチンがあり、注射用ワクチンの投与経路はさらに筋肉注射、静脈注射、皮下注射に分けられます。この詳細な市場内訳は、投与経路がワクチンの有効性、コンプライアンス、全体的な市場浸透にどのように影響するかを強調しています。最後に、オンライン薬局、小売薬局、動物病院を含む流通チャネルのセグメンテーションは、伝統的な物理的流通網を維持しながら、市場がデジタル変革に適応していることを強調しています。これらのセグメンテーション戦略を組み合わせることで、市場動向を理解し、利害関係者が多様な動物種と疾患プロファイルの異質なニーズに効果的に対応する戦略を立てるための包括的な枠組みを提供することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で人獣共通感染症の蔓延が増加
    • 世界中で動物の健康管理を推進する政府の取り組み
  • 抑制要因
    • 動物用ワクチンの研究開発および生産に関連する高コスト
  • 機会
    • 野生生物保護団体との新たなパートナーシップ
    • ワクチン投与方法の革新により投与が強化され、動物の免疫反応が改善される
  • 課題
    • 動物用ワクチンに関連する厳格な規制と承認プロセス
• 市場セグメンテーション分析
  • 製品：病原体の生物学的特性が複雑な疾患に対する防御策として、弱毒生ワクチンがますます好まれるようになっている
  • 動物の種類：ペット飼育の増加により、伴侶動物に対する動物用ワクチンの重要性が高まっている
  • 病気の種類：ウイルス感染に対処するための動物用ワクチンの必要性の高まり
  • 投与経路：血流への速やかな吸収により、IMワクチンの重要性が高まっている
  • 流通チャネル：デジタルプラットフォームの導入と利便性の向上により、オンライン薬局の選好が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 動物用ワクチン市場：製品別

• 不活化ワクチン
• 生弱毒化ワクチン
• mRNAワクチン
• 組み換えワクチン
• サブユニットワクチン

第7章 動物用ワクチン市場動物の種類別

• コンパニオンアニマル
  • 猫
  • 犬
• 家畜
  • 牛
  • 家禽
  • 羊
  • 豚

第8章 動物用ワクチン市場：疾患タイプ別

• 細菌感染症
  • クロストリジウム
  • 大腸菌
  • レプトスピラ症
  • パスツレラ
• 真菌感染症
• 寄生虫感染症
  • 外部寄生虫
  • 内部寄生虫
• ウイルス感染
  • 鳥インフルエンザウイルス
  • 牛ウイルス性下痢ウイルス（BVDV）
  • 口蹄疫ウイルス（FMDV）
  • ニューカッスル病ウイルス
  • 豚繁殖呼吸器症候群ウイルス（PRRSV）
  • 狂犬病ウイルス

第9章 動物用ワクチン市場：投与経路別

• 注射ワクチン
  • 筋肉内（IM）
  • 静脈内（IV）
  • 皮下（SC）
• 経口ワクチン

第10章 動物用ワクチン市場：流通チャネル別

• オンライン薬局
• 小売薬局
• 獣医クリニック

第11章 南北アメリカの動物用ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の動物用ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの動物用ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Biogenesis Bago S.A.
• BioVaxys Technology Corporation
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private limited
• Ceva Sante Animale
• China Animal Husbandry Industry Co., Ltd.
• Dalan Animal Health
• Elanco Animal Health Inc.
• Endovac Animal Health, LLC by Immvac Inc.
• Hester Biosciences Limited
• HIPRA, S.A.
• Indian Immunologicals Limited
• Kemin Industries, Inc.
• Merck KGaA
• Neogen Corporation
• Phibro Animal Health Corporation
• SAN Vet Holding GmbH
• Sanofi S.A.
• Seppic S.A.
• Torigen Pharmaceuticals Inc.
• Vaxxinova GmbH
• VEROVACCiNES GmbH
• Vetigenics, LLC
• Vetoquinol SA
• Virbac, Inc.
• Zoetis Inc.

LIST OF FIGURES

• FIGURE 1. ANIMAL VACCINES MARKET MULTI-CURRENCY
• FIGURE 2. ANIMAL VACCINES MARKET MULTI-LANGUAGE
• FIGURE 3. ANIMAL VACCINES MARKET RESEARCH PROCESS
• FIGURE 4. ANIMAL VACCINES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ANIMAL VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ANIMAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANIMAL VACCINES MARKET DYNAMICS
• TABLE 7. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANIMAL VACCINES MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SHEEP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANIMAL VACCINES MARKET SIZE, BY E. COLI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ECTOPARASITES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ENDOPARASITES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ANIMAL VACCINES MARKET SIZE, BY AVIAN INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ANIMAL VACCINES MARKET SIZE, BY BOVINE VIRAL DIARRHEA VIRUS (BVDV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE VIRUS (FMDV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ANIMAL VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME VIRUS (PRRSV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RABIES VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL ANIMAL VACCINES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. GLOBAL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 50. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 51. GLOBAL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. GLOBAL ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 53. GLOBAL ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 54. GLOBAL ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. AMERICAS ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 61. AMERICAS ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 62. AMERICAS ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 63. AMERICAS ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. AMERICAS ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 65. AMERICAS ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. AMERICAS ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 70. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 71. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 73. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 74. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 75. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 77. ARGENTINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 81. BRAZIL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 82. BRAZIL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. BRAZIL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 84. BRAZIL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 85. BRAZIL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 86. BRAZIL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. BRAZIL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 88. BRAZIL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. CANADA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. CANADA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 91. CANADA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 92. CANADA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 93. CANADA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. CANADA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 95. CANADA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 96. CANADA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 97. CANADA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. CANADA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 99. CANADA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 103. MEXICO ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 104. MEXICO ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. MEXICO ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 106. MEXICO ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 107. MEXICO ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 108. MEXICO ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. MEXICO ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 110. MEXICO ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 115. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 116. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 117. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 118. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 119. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 121. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. UNITED STATES ANIMAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 127. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 129. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 130. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 131. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 133. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. ASIA-PACIFIC ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 137. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 138. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 139. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 141. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 142. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 143. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 145. AUSTRALIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. CHINA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 147. CHINA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 148. CHINA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 149. CHINA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 150. CHINA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. CHINA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 152. CHINA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 153. CHINA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 154. CHINA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. CHINA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 156. CHINA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. INDIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. INDIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 159. INDIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 160. INDIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 161. INDIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. INDIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 163. INDIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 164. INDIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 165. INDIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. INDIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 167. INDIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. INDONESIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. INDONESIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 170. INDONESIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 171. INDONESIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 172. INDONESIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 173. INDONESIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 174. INDONESIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 175. INDONESIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 176. INDONESIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 177. INDONESIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 178. INDONESIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. JAPAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. JAPAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 181. JAPAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 182. JAPAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 183. JAPAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 184. JAPAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 185. JAPAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 186. JAPAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 187. JAPAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. JAPAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 189. JAPAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 192. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 193. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 194. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 195. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 196. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 197. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 198. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 199. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 200. MALAYSIA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 202. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 203. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 204. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 205. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 206. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 207. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 208. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 209. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 211. PHILIPPINES ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 213. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 215. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 216. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 218. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 219. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 220. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 222. SINGAPORE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 223. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 224. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 225. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 226. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 227. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 228. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 229. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 230. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 231. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 232. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 233. SOUTH KOREA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 234. TAIWAN ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 235. TAIWAN ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 236. TAIWAN ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 237. TAIWAN ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 238. TAIWAN ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 239. TAIWAN ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 240. TAIWAN ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 241. TAIWAN ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 242. TAIWAN ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 243. TAIWAN ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 244. TAIWAN ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 245. THAILAND ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 246. THAILAND ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 247. THAILAND ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 248. THAILAND ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 249. THAILAND ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 250. THAILAND ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 251. THAILAND ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 252. THAILAND ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 253. THAILAND ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. THAILAND ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 255. THAILAND ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 256. VIETNAM ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 257. VIETNAM ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 258. VIETNAM ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 259. VIETNAM ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 260. VIETNAM ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 261. VIETNAM ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 262. VIETNAM ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 263. VIETNAM ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 264. VIETNAM ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 265. VIETNAM ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 266. VIETNAM ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 279. DENMARK ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 280. DENMARK ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 281. DENMARK ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 282. DENMARK ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 283. DENMARK ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 284. DENMARK ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 285. DENMARK ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 286. DENMARK ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 287. DENMARK ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 288. DENMARK ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 289. DENMARK ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 290. EGYPT ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 291. EGYPT ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 292. EGYPT ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 293. EGYPT ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 294. EGYPT ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 295. EGYPT ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 296. EGYPT ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 297. EGYPT ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 298. EGYPT ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 299. EGYPT ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 300. EGYPT ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 301. FINLAND ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 302. FINLAND ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 303. FINLAND ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 304. FINLAND ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 305. FINLAND ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 306. FINLAND ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 307. FINLAND ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 308. FINLAND ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 309. FINLAND ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 310. FINLAND ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 311. FINLAND ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 312. FRANCE ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 313. FRANCE ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 314. FRANCE ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 315. FRANCE ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 316. FRANCE ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 317. FRANCE ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 318. FRANCE ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 319. FRANCE ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 320. FRANCE ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 321. FRANCE ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 322. FRANCE ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 323. GERMANY ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 324. GERMANY ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 325. GERMANY ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 326. GERMANY ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 327. GERMANY ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 328. GERMANY ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 329. GERMANY ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 330. GERMANY ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 331. GERMANY ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 332. GERMANY ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 333. GERMANY ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 334. ISRAEL ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 335. ISRAEL ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2030 (USD MILLION)
• TABLE 336. ISRAEL ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2030 (USD MILLION)
• TABLE 337. ISRAEL ANIMAL VACCINES MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2030 (USD MILLION)
• TABLE 338. ISRAEL ANIMAL VACCINES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 339. ISRAEL ANIMAL VACCINES MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 340. ISRAEL ANIMAL VACCINES MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 341. ISRAEL ANIMAL VACCINES MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
• TABLE 342. ISRAEL ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 343. ISRAEL ANIMAL VACCINES MARKET SIZE, BY INJECTABLE VACCINES, 2018-2030 (USD MILLION)
• TABLE 344. ISRAEL ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 345. ITALY ANIMAL VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 346. ITALY

The Animal Vaccines Market was valued at USD 13.69 billion in 2024 and is projected to grow to USD 14.58 billion in 2025, with a CAGR of 6.75%, reaching USD 20.27 billion by 2030.

In recent years, the animal vaccines market has emerged as a critical segment within the global health landscape, driven by growing awareness of animal health, food security, and public safety. This report provides an in-depth exploration of the evolving trends, technological advancements, and strategic imperatives that are reshaping this sector. The dynamic interplay between science, regulation, and market demand is creating opportunities and challenges that require a keen understanding of product innovations and host biology. This introduction sets the stage by outlining key themes including the role of novel vaccine development, the importance of robust clinical data, and the regulatory shifts that influence market adoption. The ongoing improvements in vaccine delivery methods and formulation techniques signify a transformative period that is redefining how veterinarians and livestock managers approach preventive animal health care. As we delve further into this comprehensive analysis, the discussion will illuminate both current practices and future growth prospects, thereby enabling decision-makers to align their strategies with emerging market signals.

The global animal vaccines landscape is characterized by ever-increasing research and development activities, integration of advanced biotechnologies, and strategic collaborations. These trends are not only fostering innovation but are also expanding the breadth of available vaccine products. As stakeholders navigate through regulatory complexities and competitive pressures, understanding these shifts becomes critical for aligning investment and operational priorities with long-term market realities.

Transformative Shifts in Market Dynamics

The animal vaccines market is currently experiencing transformative shifts that are reshaping industry dynamics and redefining competitive landscapes. Emerging technologies have paved the way for agile manufacturing processes and have significantly reduced the time-to-market for novel vaccine candidates. With pivotal advancements in genetic engineering and biotechnology, there is a marked transition from traditional vaccine formulations to innovative approaches such as mRNA and recombinant vaccines. This transformation is not solely driven by scientific breakthroughs but is also influenced by evolving regulatory frameworks that emphasize efficacy, safety, and rapid deployment in response to disease outbreaks.

A notable shift is occurring in the investment patterns, where increased funding in research and development is enabling a more personalized approach to animal immunization. Industry stakeholders are now leveraging data analytics and cutting-edge diagnostic tools to assess the unique disease profiles of different animal species, leading to more targeted vaccine solutions. Furthermore, the integration of digital health platforms has enhanced the ability to monitor post-vaccination outcomes, ensuring that real-world efficacy supports clinical trial claims. This digital transition is creating an environment where continuous feedback and adaptive manufacturing become the norm, thereby supporting a more resilient and responsive supply chain.

The emphasis on collaborative ventures between research institutions, biopharmaceutical companies, and veterinary practitioners has also intensified. Such alliances are critical in harnessing collective expertise to translate science into viable market solutions. Ultimately, the shift towards a more technologically empowered and data-informed industry underscores the potential for improved animal health outcomes, risk minimization, and a more sustainable vaccine market in the long run.

Key Segmentation Insights in Animal Vaccines

A detailed analysis of the animal vaccines market reveals multiple segmentation strategies that provide a rich understanding of the sector's diversity and depth. The product segmentation is particularly noteworthy as it encompasses a broad spectrum including inactivated vaccines, live attenuated vaccines, mRNA vaccines, recombinant vaccines, and subunit vaccines. These classifications illustrate the technological advancements and complex manufacturing processes designed to optimize immune responses across various species. This diversification in product profile enables stakeholders to address specialised needs and tailor solutions that align with distinct animal health challenges.

Moreover, segmentation based on animal type further refines market insights. The market distinguishes between companion animals and livestock, where the former, represented mainly by cats and dogs, and the latter, including cattle, poultry, sheep, and swine, drive distinct demand patterns and regulatory requirements. Such segmentation accounts for the variability in vaccine administration protocols and the differing economic considerations that underpin each segment. For instance, while companion animal vaccines are often driven by pet owner preferences and preventive health measures, vaccines for livestock animals must align with stringent food safety standards and biosecurity regulations.

The segmentation based on disease types adds another layer of granularity by focusing on bacterial infections, fungal infections, parasitic infections, and viral infections. Within this framework, bacterial infections are further divided into clostridial, Escherichia coli, leptospirosis, and pasteurella, while parasitic infections differentiate between ectoparasites and endoparasites. The viral segment covers several critical pathogens including avian influenza, bovine viral diarrhea virus, foot-and-mouth disease virus, Newcastle disease virus, porcine reproductive and respiratory syndrome virus, and rabies virus. These detailed sub-categories illustrate how the interplay between specific pathogens and vaccine responses drives innovation and market segmentation in clinical, logistical, and financial realms.

Additionally, analysis of the route of administration offers insights into the practical implications of vaccine design. The classifications include injectable and oral vaccines, with injectable routes being further delineated into intramuscular, intravenous, and subcutaneous methods. This detailed breakdown emphasizes how the route of administration can influence vaccine efficacy, compliance, and overall market penetration. Finally, the distribution channel segmentation, which includes online pharmacies, retail pharmacies, and veterinary clinics, underlines the market's adaptation to digital transformation while maintaining traditional physical distribution networks. Together, these segmentation strategies provide a comprehensive framework to understand market trends and enable stakeholders to craft strategies that effectively address the heterogeneous needs of diverse animal species and disease profiles.

Based on Product, market is studied across Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, Recombinant Vaccines, and Subunit Vaccines.

Based on Animal Type, market is studied across Companion Animals and Livestock Animals. The Companion Animals is further studied across Cats and Dogs. The Livestock Animals is further studied across Cattle, Poultry, Sheep, and Swine.

Based on Disease Type, market is studied across Bacterial Infections, Fungal Infections, Parasitic Infections, and Viral Infections. The Bacterial Infections is further studied across Clostridial, E. Coli, Leptospirosis, and Pasteurella. The Parasitic Infections is further studied across Ectoparasites and Endoparasites. The Viral Infections is further studied across Avian Influenza Virus, Bovine Viral Diarrhea Virus (BVDV), Foot-and-Mouth Disease Virus (FMDV), Newcastle Disease Virus, Porcine Reproductive & Respiratory Syndrome Virus (PRRSV), and Rabies Virus.

Based on Route of Administration, market is studied across Injectable Vaccines and Oral Vaccines. The Injectable Vaccines is further studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).

Based on Distribution Channel, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Clinics.

Key Global Regional Insights

The regional landscape of the animal vaccines market is marked by distinct geographic trends that reflect variations in economic development, regulatory environments, and consumer preferences. The Americas remain a robust market characterized by high investment in advanced biotechnologies and a proactive approach to animal health. Nations in this region have embraced innovation through substantial funding and supportive governmental policies, which in turn have fostered a dynamic environment for vaccine research and development.

In Europe, the Middle East, and Africa, there is an increasing focus on integrating modern manufacturing techniques with traditional vaccination approaches. This region is witnessing a blend of mature markets with emerging economies where modernization is gradually expanding the scope of animal health initiatives. Stakeholders are focusing on strengthening supply chains, establishing quality control measures, and leveraging regional partnerships to improve access to state-of-the-art vaccine products. These efforts are particularly significant in light of rising concerns around zoonotic diseases and the imperative for stringent health monitoring of livestock populations.

Asia-Pacific represents a rapidly evolving market driven by population growth, urbanization, and rising incomes. This region has seen a surge in demand for advanced vaccines, primarily driven by the expanding livestock sector and the growing popularity of companion animals. Significant investments in research and a burgeoning biopharmaceutical industry are fueling the adoption of innovative vaccine technologies. The interplay between traditional agricultural practices and modern health management strategies in this region is not only boosting vaccine uptake but is also creating new opportunities for market entrants. The regional analysis highlights variations in regulatory frameworks and investment trends, which underscore the importance of tailoring strategic initiatives to local contexts for sustained market growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Strategic Key Companies in the Sector

The competitive landscape in the animal vaccines market is defined by the contributions of several leading companies that are actively shaping trends through innovation and strategic collaborations. Prominent industry players such as Biogenesis Bago S.A. and BioVaxys Technology Corporation have carved out significant market positions by focusing on research-driven approaches and comprehensive solutions that cater to both companion and livestock animal segments. Companies like Boehringer Ingelheim International GmbH and Brilliant Bio Pharma Private Limited continue to define the cutting edge of clinical development with their robust portfolio of vaccine offerings.

Other influential organizations, including Ceva Sante Animale and China Animal Husbandry Industry Co., Ltd., have made substantial inroads in emerging markets by leveraging local expertise and agile manufacturing processes. Dalan Animal Health and Elanco Animal Health Inc. further exemplify the trend towards integrated solutions that merge innovative vaccine technologies with efficient distribution networks. Additionally, firms such as Endovac Animal Health LLC by Immvac Inc. and Hester Biosciences Limited are pushing the boundaries by harnessing novel biotechnology platforms to address emerging pathogens.

Companies like HIPRA, S.A. and Indian Immunologicals Limited are playing pivotal roles in expanding market reach and enhancing vaccine efficacy through targeted research initiatives. The strategic moves from Kemin Industries, Inc. and Merck KGaA have underscored the importance of global partnerships, while Neogen Corporation and Phibro Animal Health Corporation have further expanded their influence through targeted acquisitions and market-specific adaptations. SAN Vet Holding GmbH, Sanofi S.A., and Seppic S.A. stand out for their commitment to continuous innovation, even as Torigen Pharmaceuticals Inc., Vaxxinova GmbH, and VEROVACCiNES GmbH consolidate their presence through specialized product lines. These trends are complemented by the focused efforts of Vetigenics LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc., whose diverse strategies emphasize targeted research, agile manufacturing, and an unwavering commitment to improving animal health on a global scale. Their contributions not only drive market innovation but also emphasize a commitment to quality, efficacy, and global health standards.

The report delves into recent significant developments in the Animal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Biogenesis Bago S.A., BioVaxys Technology Corporation, Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private limited, Ceva Sante Animale, China Animal Husbandry Industry Co., Ltd., Dalan Animal Health, Elanco Animal Health Inc., Endovac Animal Health, LLC by Immvac Inc., Hester Biosciences Limited, HIPRA, S.A., Indian Immunologicals Limited, Kemin Industries, Inc., Merck KGaA, Neogen Corporation, Phibro Animal Health Corporation, SAN Vet Holding GmbH, Sanofi S.A., Seppic S.A., Torigen Pharmaceuticals Inc., Vaxxinova GmbH, VEROVACCiNES GmbH, Vetigenics, LLC, Vetoquinol SA, Virbac, Inc., and Zoetis Inc.. Actionable Recommendations for Industry Leaders

For industry leaders operating in the animal vaccines market, several actionable recommendations are emerging from this comprehensive analysis. First, it is imperative to invest strategically in research and development initiatives that embrace novel vaccine technologies such as mRNA and recombinant platforms. Emphasizing collaborative studies with research institutions and leveraging digital health solutions can streamline development timelines and enhance vaccine efficacy. Capitalizing on data analytics to monitor post-market performance will also support targeted improvements in existing formulations.

Furthermore, strategic portfolio diversification across various product types addresses the distinct needs of both companion and livestock animals. Companies should consider integrating product development strategies that align with comprehensive disease coverage, ranging from bacterial to viral infections. Such diversification not only mitigates risk but also offers new revenue streams by addressing niche market demands.

Enhancing the efficiency of vaccine delivery channels is another key recommendation. Whether deploying injectable vaccines across intramuscular, intravenous, and subcutaneous routes or optimizing oral vaccine formulations, focusing on logistical and clinical efficiencies remains critical. In addition, refining distribution strategies across online platforms, retail pharmacies, and veterinary clinics can improve market penetration and consumer accessibility.

Finally, maintain adaptable regulatory and market strategies that respond dynamically to global trends. This includes proactive engagement with regulatory authorities to ensure alignment with evolving standards, especially in regions with rapidly changing market conditions. By fostering strategic alliances and pursuing regional customization of products and services, industry leaders can better position their organizations to capitalize on emerging opportunities and navigate the complexities of a dynamic global marketplace.

Conclusion and Future Outlook

In conclusion, the animal vaccines market is undergoing a period of significant transformation that is being shaped by technological innovation, strategic segmentation, and dynamic regional factors. This evolving landscape presents both challenges and opportunities that require industry stakeholders to be agile, forward-thinking, and committed to continuous improvement. The in-depth analysis presented herein highlights the importance of embracing novel vaccine platforms and integrating nuanced insights from product, animal type, and disease segmentation to create targeted, effective solutions.

Looking forward, the drive towards digital health integration, coupled with an increased focus on regulatory compliance and strategic global partnerships, will define the pathway for sustained growth and innovation. The synthesis of these industry trends not only affirms the critical role of animal vaccines in achieving improved animal health outcomes but also underscores the broader implications for food safety, public health, and economic development. As decision-makers recalibrate their strategies, the insights provided in this report offer a robust foundation for navigating a complex but promising market landscape.

The future of animal vaccines is bright, bolstered by continuous advancements in technology and science. Stakeholders must remain vigilant and responsive to emerging trends, ensuring that their strategic initiatives are backed by rigorous research and a deep understanding of regional market dynamics. This commitment to adaptive and innovative practices will be the key to unlocking new opportunities and sustaining long-term success in the animal vaccines sector.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of zoonotic diseases worldwide
    • 5.1.1.2. Government initiatives promoting animal health care globally
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the R&D and production of animal vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging partnerships with wildlife conservation organizations
    • 5.1.3.2. Innovations in vaccine delivery methods enhancing administration and improving animal immune responses
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations and approval processes associated with animal vaccines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Increasing preference for attenuated live vaccines to protect against diseases with complex pathogen biology
  • 5.2.2. Animal Type: Rising significance of animal vaccines for companion animals owing to increasing pet ownership
  • 5.2.3. Disease Type: Increasing need for animal vaccines to deal with viral infections
  • 5.2.4. Route of Administration: Rising importance of IM vaccines owing to their quick absorption into the bloodstream
  • 5.2.5. Distribution Channel: Increasing preference for online pharmacies owing to growing adoption of digital platforms and convenience
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Animal Vaccines Market, by Product

• 6.1. Introduction
• 6.2. Inactivated Vaccines
• 6.3. Live Attenuated Vaccines
• 6.4. mRNA Vaccines
• 6.5. Recombinant Vaccines
• 6.6. Subunit Vaccines

7. Animal Vaccines Market, by Animal Type

• 7.1. Introduction
• 7.2. Companion Animals
  • 7.2.1. Cats
  • 7.2.2. Dogs
• 7.3. Livestock Animals
  • 7.3.1. Cattle
  • 7.3.2. Poultry
  • 7.3.3. Sheep
  • 7.3.4. Swine

8. Animal Vaccines Market, by Disease Type

• 8.1. Introduction
• 8.2. Bacterial Infections
  • 8.2.1. Clostridial
  • 8.2.2. E. Coli
  • 8.2.3. Leptospirosis
  • 8.2.4. Pasteurella
• 8.3. Fungal Infections
• 8.4. Parasitic Infections
  • 8.4.1. Ectoparasites
  • 8.4.2. Endoparasites
• 8.5. Viral Infections
  • 8.5.1. Avian Influenza Virus
  • 8.5.2. Bovine Viral Diarrhea Virus (BVDV)
  • 8.5.3. Foot-and-Mouth Disease Virus (FMDV)
  • 8.5.4. Newcastle Disease Virus
  • 8.5.5. Porcine Reproductive & Respiratory Syndrome Virus (PRRSV)
  • 8.5.6. Rabies Virus

9. Animal Vaccines Market, by Route of Administration

• 9.1. Introduction
• 9.2. Injectable Vaccines
  • 9.2.1. Intramuscular (IM)
  • 9.2.2. Intravenous (IV)
  • 9.2.3. Subcutaneous (SC)
• 9.3. Oral Vaccines

10. Animal Vaccines Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Online Pharmacies
• 10.3. Retail Pharmacies
• 10.4. Veterinary Clinics

11. Americas Animal Vaccines Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Animal Vaccines Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Animal Vaccines Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Anivive secures USD 20 million investment from Leonid Capital Partners to develop the next generation of pet health
  • 14.3.2. Boehringer Ingelheim unveils next-gen vaccine in India, tackling rising Marek's disease challenges
  • 14.3.3. BioVaxys and SpayVac expand vaccine production to advance wildlife contraception and aquaculture solutions
  • 14.3.4. Ceva Animal Health expands vaccine production with new Hungarian facility
  • 14.3.5. Merck Animal Health unveils RNA-particle feline vaccine to target feline leukemia virus
  • 14.3.6. Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
  • 14.3.7. University of Missouri's innovative vaccine offers new hope against bovine anaplasmosis
  • 14.3.8. ICAR-CIBA and Indian Immunologicals Limited entered into an agreement for commercial development of fish vaccine
  • 14.3.9. Fischer MV partners with BAV to launch livestock and aquaculture vaccines in India
  • 14.3.10. Merck Animal Health's strategic acquisition of Elanco's aqua business enhances vaccine and treatment portfolio in aquaculture sector
  • 14.3.11. Huvepharma's EUR 72 million investment in Bulgarian veterinary vaccine plant to enhance global supply chain
  • 14.3.12. Pioneering partnership enhances African swine fever vaccine development for global pig protection
  • 14.3.13. Zoetis invests AUD 350 million to amplify vaccine production in Australia, bolstering animal health and industry collaboration
  • 14.3.14. Virbac's strategic acquisition of Sasaeah boosts its market position and innovation in Japan's animal vaccine market
  • 14.3.15. Zendal and CSIC introduce innovative DNA vaccine to combat leishmaniasis
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Virbac, Inc.
  • 14.4.2. Phibro Animal Health Corporation
  • 14.4.3. Ceva Sante Animale
  • 14.4.4. Boehringer Ingelheim International GmbH

Companies Mentioned

• 1. Biogenesis Bago S.A.
• 2. BioVaxys Technology Corporation
• 3. Boehringer Ingelheim International GmbH
• 4. Brilliant Bio Pharma Private limited
• 5. Ceva Sante Animale
• 6. China Animal Husbandry Industry Co., Ltd.
• 7. Dalan Animal Health
• 8. Elanco Animal Health Inc.
• 9. Endovac Animal Health, LLC by Immvac Inc.
• 10. Hester Biosciences Limited
• 11. HIPRA, S.A.
• 12. Indian Immunologicals Limited
• 13. Kemin Industries, Inc.
• 14. Merck KGaA
• 15. Neogen Corporation
• 16. Phibro Animal Health Corporation
• 17. SAN Vet Holding GmbH
• 18. Sanofi S.A.
• 19. Seppic S.A.
• 20. Torigen Pharmaceuticals Inc.
• 21. Vaxxinova GmbH
• 22. VEROVACCiNES GmbH
• 23. Vetigenics, LLC
• 24. Vetoquinol SA
• 25. Virbac, Inc.
• 26. Zoetis Inc.